Study of a Red Blood Cell Deformability Parameter in Patients With Sickle Cell Disease (Drepaforme)
Primary Purpose
Sickle Cell Disease
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Micro-blood sampling
Sponsored by
About this trial
This is an interventional other trial for Sickle Cell Disease
Eligibility Criteria
Inclusion Criteria:
- Homozygous SS or SB° sickle cell patients
- Person without regular blood transfusion
Exclusion Criteria:
- Other general diseases
- Psychiatric disorder
- Alcoholics
- Minors
- Absence of informed consent
- Pregnant or lactating woman
- Person under guardianship
- Person living in a health or social institution
- Person in emergency
- Person out of healthcare system
- Person deprived of liberty
- Person who has received a blood transfusion in the previous 3 months
- Person with regular blood transfusion or in a blood transfusion program
Sites / Locations
- Assistance Publique Hôpitaux de Marseille
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
patients with sickle cell disease
Arm Description
Outcomes
Primary Outcome Measures
cytoplasmic viscosity measurement of red blood cells
Determination of the cytoplasmic viscosity parameter variations by measuring percentage of tanktreading (nature of movement of cells in a shear flow) from a micro-blood sample
Secondary Outcome Measures
Full Information
NCT ID
NCT03977532
First Posted
June 3, 2019
Last Updated
August 3, 2023
Sponsor
Assistance Publique Hopitaux De Marseille
1. Study Identification
Unique Protocol Identification Number
NCT03977532
Brief Title
Study of a Red Blood Cell Deformability Parameter in Patients With Sickle Cell Disease
Acronym
Drepaforme
Official Title
Study of a Red Blood Cell Deformability Parameter in Patients With Sickle Cell Disease, at Basal State and During Vaso-occlusive Crisis
Study Type
Interventional
2. Study Status
Record Verification Date
August 2023
Overall Recruitment Status
Completed
Study Start Date
September 14, 2018 (Actual)
Primary Completion Date
December 11, 2019 (Actual)
Study Completion Date
August 3, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Assistance Publique Hopitaux De Marseille
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Sickle cell disease is the most common genetic disease in the world. It results in the synthesis of an abnormal hemoglobin (HbS) which, in its deoxygenated form, polymerizes and causes structural changes in red blood cells (RBCs). They become more rigid and less deformable. The fragility of sickle-cell RBCs leads to their massive destruction, leading to chronic anemia (i.e. low hemoglobin in the blood) and to low tissue oxygenation. More rigid and less deformable, sickle-shaped RBCs tend to obstruct microvessels, leading to particularly painful vaso-occlusive crisis (VOC), which can cause organ failure (spleen, kidneys, brain, lungs, heart, liver, bone ...) and patient's lifethreatning. A preliminary work on red blood cells of sickle cell patients showed alteration of a parameter measuring the overall deformability of RBCs by assessing the nature of their movement in a shear flow. This parameter is altered sickle cell patients at basal state compared to a population of healthy individuals. This alteration is increased when sickle cell patients are in crisis.
The main objective of this project is to study the evolution of this parameter in sickle cell patients according to their health status (basal state vs vaso-occlusive crisis). The investigators hypothesize that the alteration of the RBC deformability parameter is significant before symptoms of vaso-occlusive crisis (several hours to several days). The main objective is a weekly analysis of the evolution of the parameter in 30 sickle cell patients (SS or SB°) in the basal state and daily in at least 6 patients at the beginning, during and just after a vaso-occlusive crisis. The comparison between the parameter measured in a subject in the basal state and in the same subject in crisis will be performed. The criteria for the presence of a vaso-occlusive crisis were: the appearance of a attacks of pain affecting at least two territories +/- fever> 38.3 +/- dyspnea and / or sputum. The investigators will differentiate the moderate VOC managed at home with low-level analgesics and VOC requiring hospitalization. The number of days of hospitalization, the occurrence of thrombotic complications, the degree of anemia and hemolysis will be noted. The measurement of the parameter will be performed on a capillary sampling of 40 microliters performed at the fingertip, weekly outside crises and daily when a crisis occurs.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sickle Cell Disease
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
21 (Actual)
8. Arms, Groups, and Interventions
Arm Title
patients with sickle cell disease
Arm Type
Experimental
Intervention Type
Other
Intervention Name(s)
Micro-blood sampling
Intervention Description
capillary sampling of 40 microliters performed at the fingertip
Primary Outcome Measure Information:
Title
cytoplasmic viscosity measurement of red blood cells
Description
Determination of the cytoplasmic viscosity parameter variations by measuring percentage of tanktreading (nature of movement of cells in a shear flow) from a micro-blood sample
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Homozygous SS or SB° sickle cell patients
Person without regular blood transfusion
Exclusion Criteria:
Other general diseases
Psychiatric disorder
Alcoholics
Minors
Absence of informed consent
Pregnant or lactating woman
Person under guardianship
Person living in a health or social institution
Person in emergency
Person out of healthcare system
Person deprived of liberty
Person who has received a blood transfusion in the previous 3 months
Person with regular blood transfusion or in a blood transfusion program
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Emilie Garrido Pradalié
Organizational Affiliation
Assistance Publique Hôpitaux de Marseille
Official's Role
Study Director
Facility Information:
Facility Name
Assistance Publique Hôpitaux de Marseille
City
Marseille
ZIP/Postal Code
13005
Country
France
12. IPD Sharing Statement
Learn more about this trial
Study of a Red Blood Cell Deformability Parameter in Patients With Sickle Cell Disease
We'll reach out to this number within 24 hrs